Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand.
Drugs. 2017 Nov;77(17):1917-1923. doi: 10.1007/s40265-017-0825-y.
Tivozanib (Fotivda) is an oral, potent and highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor that has been approved in the EU, Iceland and Norway for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mammalian target of rapamycin (mTOR) pathway inhibitor-naive following disease progression after one prior treatment with cytokine therapy for advanced RCC. Tivozanib is at various stages of development in other countries for advanced RCC and advanced solid tumours. This article summarizes the milestones in the development of tivozanib leading to this first global approval in Europe for the treatment of adults with advanced RCC.
替沃扎尼布（Fotivda）是一种口服的、强效的、高度选择性的血管内皮生长因子受体（VEGFR）抑制剂，已在欧盟、冰岛和挪威获批，用于治疗晚期肾细胞癌（RCC）的成人患者的一线治疗，以及用于在先前接受过晚期 RCC 的细胞因子治疗后疾病进展的、对 VEGFR 和哺乳动物雷帕霉素靶蛋白（mTOR）通路抑制剂初治的成人患者。替沃扎尼布在其他国家也处于治疗晚期 RCC 和晚期实体瘤的不同开发阶段。本文总结了替沃扎尼布的开发历程中的重要里程碑，从而使其在欧洲获得了首个用于治疗成人晚期 RCC 的全球批准。
